Octreotide and Octreotide-derived delivery systems
Pharmaceutical peptide Octreotide is a somatostatin analog with targeting and therapeutic abilities. Over the last decades, Octreotide has been developed and approved to treat acromegaly and neuroendocrine tumours, and Octreotide-based radioactive conjugates have been leveraged clinically to detect small neuroendocrine tumour sites. Meanwhile, variety of Octreotide-derived delivery strategies have been proposed and explored for tumour targeted therapeutics or diagnostics in preclinical or clinical settings. In this review, we especially focus on the preclinical development and applications of Octreotide-derived drug delivery systems, diagnostic nanosystems, therapeutic nanosystems and multifunctional nanosystems, we also briefly discuss challenges and prospects of these Octreotide-derived delivery systems.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:31 |
|---|---|
| Enthalten in: |
Journal of drug targeting - 31(2023), 6 vom: 21. Juli, Seite 569-584 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Fan, Mingliang [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Cancer therapy |
|---|
| Anmerkungen: |
Date Revised 17.10.2023 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.1080/1061186X.2023.2216895 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM357141687 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM357141687 | ||
| 003 | DE-627 | ||
| 005 | 20231226071943.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/1061186X.2023.2216895 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1190.xml |
| 035 | |a (DE-627)NLM357141687 | ||
| 035 | |a (NLM)37211679 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Fan, Mingliang |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Octreotide and Octreotide-derived delivery systems |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 17.10.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a Pharmaceutical peptide Octreotide is a somatostatin analog with targeting and therapeutic abilities. Over the last decades, Octreotide has been developed and approved to treat acromegaly and neuroendocrine tumours, and Octreotide-based radioactive conjugates have been leveraged clinically to detect small neuroendocrine tumour sites. Meanwhile, variety of Octreotide-derived delivery strategies have been proposed and explored for tumour targeted therapeutics or diagnostics in preclinical or clinical settings. In this review, we especially focus on the preclinical development and applications of Octreotide-derived drug delivery systems, diagnostic nanosystems, therapeutic nanosystems and multifunctional nanosystems, we also briefly discuss challenges and prospects of these Octreotide-derived delivery systems | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Octreotide | |
| 650 | 4 | |a cancer therapy | |
| 650 | 4 | |a diagnostic nanosystems | |
| 650 | 4 | |a drug delivery | |
| 650 | 4 | |a therapeutic nanosystems | |
| 650 | 4 | |a tumour targeting | |
| 700 | 1 | |a Huang, Yue |e verfasserin |4 aut | |
| 700 | 1 | |a Zhu, Xinlin |e verfasserin |4 aut | |
| 700 | 1 | |a Zheng, Jiayu |e verfasserin |4 aut | |
| 700 | 1 | |a Du, Mingwei |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of drug targeting |d 1996 |g 31(2023), 6 vom: 21. Juli, Seite 569-584 |w (DE-627)NLM074733958 |x 1029-2330 |7 nnns |
| 773 | 1 | 8 | |g volume:31 |g year:2023 |g number:6 |g day:21 |g month:07 |g pages:569-584 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/1061186X.2023.2216895 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 31 |j 2023 |e 6 |b 21 |c 07 |h 569-584 | ||